BR0315731A - Comprimidos orais de liberação prolongada e métodos para fabricar e usar os mesmos - Google Patents

Comprimidos orais de liberação prolongada e métodos para fabricar e usar os mesmos

Info

Publication number
BR0315731A
BR0315731A BR0315731-8A BR0315731A BR0315731A BR 0315731 A BR0315731 A BR 0315731A BR 0315731 A BR0315731 A BR 0315731A BR 0315731 A BR0315731 A BR 0315731A
Authority
BR
Brazil
Prior art keywords
methods
present
manufacturing
oral
extended
Prior art date
Application number
BR0315731-8A
Other languages
English (en)
Inventor
Robert M Noack
John M Heimlich
Ernest J Lee
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0315731A publication Critical patent/BR0315731A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPRIMIDOS ORAIS DE LIBERAçãO PROLONGADA E MéTODOS PARA FABRICAR E USAR OS MESMOS". A presente invenção refere-se a formas de dosagem orais para liberação prolongada, incluindo uma forma de dosagem para liberação prolongada independente do pH, de pelo menos um fármaco para um indivíduo. A presente invenção refere-se também a métodos de fabricação e utilização das formas de dosagem para tratar ou prevenir um indivíduo contra várias condições. Também são fornecidas formulações de liberação prolongada específicas de base livre de clindamicina cristalina. As formulações orais de base livre de clindamicina cristalina da presente invenção proporcionam um meio para tratar ou prevenir infecções com bactérias gram-positivas com um número mínimo de tratamentos por dia, potencialmente tão pouco quanto uma vez ou duas vezes ao dia.
BR0315731-8A 2002-10-30 2003-10-27 Comprimidos orais de liberação prolongada e métodos para fabricar e usar os mesmos BR0315731A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42241802P 2002-10-30 2002-10-30
PCT/US2003/033903 WO2004041244A2 (en) 2002-10-30 2003-10-27 Oral extended release tablets and methods of making and using the same

Publications (1)

Publication Number Publication Date
BR0315731A true BR0315731A (pt) 2005-09-06

Family

ID=32312502

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315731-8A BR0315731A (pt) 2002-10-30 2003-10-27 Comprimidos orais de liberação prolongada e métodos para fabricar e usar os mesmos

Country Status (10)

Country Link
US (1) US20040146556A1 (pt)
EP (1) EP1558211A2 (pt)
JP (1) JP2006507298A (pt)
AR (1) AR041856A1 (pt)
AU (1) AU2003284942A1 (pt)
BR (1) BR0315731A (pt)
CA (1) CA2501324A1 (pt)
MX (1) MXPA05004648A (pt)
TW (1) TW200413032A (pt)
WO (1) WO2004041244A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
RU2414241C2 (ru) * 2005-08-26 2011-03-20 БиПиЭсАй ХОЛДИНГЗ, ИНК. Лекарственные композиции, содержащие гипромеллозные матрицы контролируемого высвобождения
US20120251588A1 (en) 2011-03-30 2012-10-04 Miyuki Fukasawa Coating Composition, Solid Preparation Coated Therewith, and Method for Preparing Solid Preparation
US20140302138A1 (en) * 2011-10-14 2014-10-09 Micro Labs Limited Extended release pharmaceutical compositions containing carbamazepine
EP2790677A4 (en) * 2011-12-16 2015-05-06 Celanese Eva Performance Polymers Inc CONTROLLED RELEASE EXCIPIENTS HAVING ARCHITECTURES WITH APPROPRIATE INTERSTITIAL SPACES
EP2916828A1 (en) * 2012-11-07 2015-09-16 Nazura Biohealth Inc. Gras enteric coating formulations and methods of making and using same
JP5836980B2 (ja) * 2013-01-11 2015-12-24 信越化学工業株式会社 薬物含有粒子、固形製剤及び薬物含有粒子の製造方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246013A1 (de) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
GB1456365A (en) * 1972-10-06 1976-11-24 Gist Brocades Nv Controlled release composition
US4135514A (en) * 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
DE2556561C2 (de) * 1975-12-16 1983-04-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Herstellung von porösen Tabletten
JPS6048484B2 (ja) * 1980-05-20 1985-10-28 アルザ・コ−ポレ−シヨン 拡散性活性剤デイスペンサ−
JPS5758631A (en) * 1980-09-24 1982-04-08 Toyo Jozo Co Ltd Coating composition
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
US4880631A (en) * 1987-09-24 1989-11-14 Merck & Co., Inc. Controlled porosity osmotic pump
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
JPH0791184B2 (ja) * 1988-03-31 1995-10-04 田辺製薬株式会社 放出制御型製剤およびその製法
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5670170A (en) * 1990-04-27 1997-09-23 Beecham Group P.L.C. Pharamaceutical formulation
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
IT1260505B (it) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE4404018A1 (de) * 1994-02-09 1995-08-10 Merck Patent Gmbh Protrahiert freisetzende Darreichungsformen enthaltend Clindamycin-Palmitat
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
HUT77530A (hu) * 1994-05-06 1998-05-28 Pfizer Inc. Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
JPH0826977A (ja) * 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd 溶出制御型経口製剤
EP0807433A4 (en) * 1994-12-27 2005-12-28 Akzo Nobel Nv PREPARING WITH DELAYED RELEASE
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP3134187B2 (ja) * 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
IL118932A0 (en) * 1996-07-24 1996-10-31 Dexcel Ltd Controlled release tablets
US6074669A (en) * 1997-01-20 2000-06-13 Ranbaxy Laboratories Limited Controlled drug delivery system for diltiazem
US5881388A (en) * 1998-04-06 1999-03-16 Pratt; Kevin G. Glove with finger grip inserts
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
MXPA01004381A (es) * 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
US6150410A (en) * 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
JP2001055322A (ja) * 1999-08-18 2001-02-27 Tanabe Seiyaku Co Ltd パルス放出型製剤
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030073648A1 (en) * 2001-08-28 2003-04-17 Chao Robert S. Crystaline clindamycin free base

Also Published As

Publication number Publication date
WO2004041244A2 (en) 2004-05-21
US20040146556A1 (en) 2004-07-29
TW200413032A (en) 2004-08-01
JP2006507298A (ja) 2006-03-02
EP1558211A2 (en) 2005-08-03
MXPA05004648A (es) 2005-06-08
AU2003284942A1 (en) 2004-06-07
WO2004041244A3 (en) 2004-07-15
AR041856A1 (es) 2005-06-01
AU2003284942A8 (en) 2004-06-07
CA2501324A1 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
CY1110019T1 (el) Συνδυασμενη θεραπεια με υποκατεστημενες οξαζολιδινονες
BRPI0415639A (pt) formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
UY26380A1 (es) Inhibidores de fab i
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
GT200100183A (es) Derivados de quinolina y quinazolina.
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
DE50310516D1 (de) Fredericamycin-derivate
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
GB0222514D0 (en) Organic compounds
CY1108808T1 (el) Ενωσεις μοτιλιδης
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
CY1112167T1 (el) Νεα χρηση αντιβιοτικων κινολονης
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
MXPA05013974A (es) Formulaciones farmaceuticas de compuestos de inhibicion amiloidea.
ES2186550B2 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
BR0315731A (pt) Comprimidos orais de liberação prolongada e métodos para fabricar e usar os mesmos
MA27059A1 (fr) Azithromycine en dose unique
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
ES2178761T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de infe cciones cutaneas.
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
UY28542A1 (es) Amidas macrocíclicas antibacterianas
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A , E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.